CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2025; 9: (5) ; 150-152 ; DOI: 10.12208/j.ijcr.20250259.

Research on the targeted delivery system of antitumor drugs
抗肿瘤药物的靶向递送系统研究

作者: 黄鹏贵 *

江西东抚制药有限公司 江西抚州

*通讯作者: 黄鹏贵,单位:江西东抚制药有限公司 江西抚州;

发布时间: 2025-05-29 总浏览量: 24

摘要

抗肿瘤药物的靶向递送系统旨在提高治疗效果并减少副作用,是当前癌症治疗领域的一个研究热点。本论文探讨了如何通过设计和优化靶向递送系统来增强抗肿瘤药物的疗效。首先分析了传统化疗方案中存在的局限性,包括对正常细胞的高毒性以及较低的肿瘤选择性。随后,详细讨论了几种先进的靶向策略,如抗体介导的药物传递、纳米颗粒载体的应用等,并评估了这些方法在临床前和临床试验中的表现。强调了进一步优化靶向递送系统的重要性,以实现更高效、更具选择性的抗癌治疗。

关键词: 抗肿瘤药物;靶向递送;纳米颗粒;抗体介导

Abstract

The targeted delivery system of antitumor drugs aims to improve the therapeutic effect and reduce side effects, which is a research hotspot in the current field of cancer treatment. This thesis explores how to enhance the efficacy of antitumor drugs by designing and optimizing the targeted delivery system. Firstly, the limitations of traditional chemotherapy regimens are analyzed, including high toxicity to normal cells and low tumor selectivity. Subsequently, several advanced targeted strategies, such as antibody-mediated drug delivery and the application of nanoparticle carriers, are discussed in detail, and the performance of these methods in preclinical and clinical trials is evaluated. The importance of further optimizing the targeted delivery system is emphasized to achieve more efficient and selective anticancer treatment.

Key words: Antitumor drugs; Targeted delivery; Nanoparticles; Antibody-Mediated

参考文献 References

[1] 董雪荣,贾立华.新型脂质体在抗肿瘤药物研究中的进展[J].临床药物治疗杂志,2025,23(03):11-18.

[2] 邵万飞.基于CD44靶向的双药物递送系统及抗肿瘤研究[D].扬州大学,2024.

[3] 胡浩田.基于聚己内酯的共聚物纳米胶束及其用于抗肿瘤药物靶向递送的研究[D].常州大学,2024.

[4] 于家乐.TfR亲和肽-阿霉素偶联物的制备与体外靶向抗肿瘤活性研究[D].承德医学院,2024.

[5] 陵廷贤,多种抗肿瘤机制的药物靶向递送系统治疗骨肉瘤的研究.四川省,四川大学,2023-06-08. 

[6] 赵婷婷,蔡泽东,杜琳琳,等.喜树碱类抗肿瘤药物的递送系统研究[J].中国新药杂志,2023,32(03):246-254.

[7] 张强.抗肿瘤药物靶向递送系统专刊评述[J].药学学报,2022,57(01):13.

[8] 孙飘,丁杨,周建平.铂类抗肿瘤药物纳米递送系统研究进展[J].中国医药工业杂志,2019,50(12):1383-1392.

引用本文

黄鹏贵, 抗肿瘤药物的靶向递送系统研究[J]. 国际临床研究杂志, 2025; 9: (5) : 150-152.